FDA Approves Regeneron-Sanofi's Dupixent for COPD Treatment

Dupixent becomes the first biologic medicine approved in the U.S. for chronic obstructive pulmonary disease, expanding its therapeutic applications.

Dupixent, developed by Regeneron and Sanofi, has received FDA approval for treating chronic obstructive pulmonary disease (COPD).
The approval is based on Phase 3 trials showing a significant reduction in COPD exacerbations and improved lung function.
This marks the first biologic treatment approved in the U.S. for COPD, targeting patients with an eosinophilic phenotype.
Dupixent has previously been approved for other conditions such as atopic dermatitis and asthma.
The drug is also approved for COPD in China and the EU, with ongoing regulatory reviews in other countries.